Valuation: ADC Therapeutics SA

Market Cap 179M 159M 147M 134M 253M 16.96B 257M 1.77B 694M 8.85B 671M 657M 28.22B P/E 2026 *
-1.86x
P/E 2027 * -2.07x
Enterprise Value 179M 159M 147M 134M 253M 16.96B 257M 1.77B 694M 8.85B 671M 657M 28.22B EV / Sales 2026 *
2.22x
EV / Sales 2027 * 1.77x
Free-Float
83.9%
Yield 2026 *
-
Yield 2027 * -
1 day-6.04%
1 week-19.08%
Current month+14.75%
1 month+33.33%
3 months+3.70%
6 months-67.29%
Current year-60.34%
1 week 1.4
Extreme 1.4
1.86
1 month 1.04
Extreme 1.035
1.87
Current year 0.78
Extreme 0.7796
4.98
1 year 0.78
Extreme 0.7796
4.98
3 years 0.36
Extreme 0.359908
6.04
5 years 0.36
Extreme 0.359908
32
10 years 0.36
Extreme 0.359908
56.59
Manager TitleAgeSince
Chief Executive Officer 53 2022-05-08
Director of Finance/CFO 54 2022-12-18
Chief Tech/Sci/R&D Officer 52 2024-09-30
Director TitleAgeSince
Director/Board Member 67 2019-05-31
Director/Board Member 53 2018-05-31
Chairman 59 2020-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Free

Chief Executive Officer

675,000 0.5307%
6/30/26 Free

Chief Financial Officer

203,700 0.1602%
6/30/26 Free

Chief Technology Officer

213,900 0.1682%
Change 5-day change 1-year change 3-year change Capi.($)
-6.04%-19.08%-65.69%+91.99% 179M
-6.60%-8.56%+49.38%+64.90% 65B
+0.03%+5.56%+9.10%+75.22% 51.2B
-4.09%-0.11%+2.22%+55.67% 51.19B
-1.53%+2.70%+30.48%+41.25% 43.93B
-1.34%+4.12%+16.64%+120.28% 41.96B
-5.97%-6.22%+228.95%+483.48% 38.14B
+6.53%+8.02%+16.40%+56.32% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
-1.07%+2.33%+19.43%+20.40% 22.5B
Average -2.10%-2.22%+34.40%+101.13% 37.25B
Weighted average by Cap. -2.20%-0.51%+44.19%+103.65%

Financials

2026 *2027 *
Net sales 80.55M 71.6M 66.37M 60.38M 114M 7.64B 116M 798M 313M 3.99B 302M 296M 12.72B 101M 89.73M 83.17M 75.67M 143M 9.58B 145M 1B 392M 5B 379M 371M 15.94B
Net income -119M -106M -98.24M -89.38M -169M -11.32B -171M -1.18B -463M -5.91B -447M -438M -18.83B -119M -106M -98.15M -89.3M -169M -11.31B -171M -1.18B -463M -5.9B -447M -438M -18.81B
Net Debt - -
Projected Income Statement - Annual - ADC Therapeutics SA
Logo ADC Therapeutics SA
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Employees
191
Date Price Change Volume
26-10-16 US$1.400 -6.04% 799,525
26-10-15 US$1.490 +2.76% 1,331,061
26-10-14 US$1.450 -14.71% 1,741,916
26-10-13 US$1.700 -8.60% 3,325,278
26-10-12 US$1.860 +7.51% 1,593,120
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - ADC Therapeutics SA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.400USD
Average target price
3.333USD
Spread / Average Target
+138.10%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ADC Therapeutics SA
  1. Stock Market
  2. Stocks
  3. ADCT Stock